AstraZeneca plc: PharmaVitae Profile

Tipo:	Marktstudie
Año:	06/2010
Publicador:	Datamonitor
Idioma:	Inglés
Disponibilidad:	disponible

Caracteristicas de este estudio de mercado:

Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector

Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune

Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2015

98 Pages

Sobre este articulo de mercado:

Introduction This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline an.....

Mas sobre este articulo de mercado

Precio **
(Formato del reporte):

5.700,00$ neto SlidePack

libre de costos de envio
**Importante: Todos los precios son netos sin impuestos. Depende del país y de su tipo de empresa para pagar los impuestos. Si usted nos da su dirección de facturación, el monto total correcto será indicado en la siguiente orden de proceso. Para más información de impuestos y precios usted nos encuentra en nuestros FAQs

	Más Estudios de Datamonitor: Epidemiology: HIV – Antiretrovirals prevail as patient population grows Merck & Co., Inc.: PharmaVitae Report Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate Turkey: Generics and Biosimilars Overview What Consumers Want: Checking Accounts in the USA 2011 [Más...]

	Nota: Datamonitor: AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty Having signed a license agreement with AstraZeneca, Rigel has boosted the prospects for R788, its RA drug. However, Phase III trials must address certain safety signals and reassure physicians of its efficacy in key patient populations. Prominent product differentiation will also be vital for the drug to compete with Pfizer's JAK inhibitor, which is set to reach the market two years ahead of it. After a mixed ending to 2009, Rigel Pharmaceuticals has found its feet in early 2010 in the form of a par... [Más...]
	Datamonitor: Slow growth in cardiovascular disease will be offset by prospects in diabetes New Datamonitor research has revealed that pharmaceutical companies will struggle to profit from the cardiovascular disease market over the next decade, despite growing drug usage. Patent expiries and generic competition will have a major impact and Datamonitor expects only AstraZeneca and [Más...]

Adquirir una cesta de compras

AstraZeneca plc: PharmaVitae Profile

Datamonitor: AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty

Datamonitor: Slow growth in cardiovascular disease will be offset by prospects in diabetes

Copyright 2012 by dynamic technologies GmbH